These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24217698)

  • 1. Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.
    Dickinson L; Chaponda M; Carr DF; van Oosterhout JJ; Kumwenda J; Lalloo DG; Pirmohamed M; Heyderman RS; Khoo SH
    Antimicrob Agents Chemother; 2014; 58(2):706-12. PubMed ID: 24217698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.
    Chou M; Bertrand J; Segeral O; Verstuyft C; Borand L; Comets E; Le Tiec C; Becquemont L; Ouk V; Mentre F; Taburet AM
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4432-9. PubMed ID: 20696882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations.
    Carr DF; Chaponda M; Cornejo Castro EM; Jorgensen AL; Khoo S; Van Oosterhout JJ; Dandara C; Kampira E; Ssali F; Munderi P; Lalloo DG; Heyderman RS; Pirmohamed M
    J Antimicrob Chemother; 2014 Dec; 69(12):3329-34. PubMed ID: 25147095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
    Heil SG; van der Ende ME; Schenk PW; van der Heiden I; Lindemans J; Burger D; van Schaik RH
    Ther Drug Monit; 2012 Apr; 34(2):153-9. PubMed ID: 22354160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.
    Calcagno A; D'Avolio A; Simiele M; Cusato J; Rostagno R; Libanore V; Baietto L; Siccardi M; Bonora S; Di Perri G
    Br J Clin Pharmacol; 2012 Jul; 74(1):134-40. PubMed ID: 22680342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
    Wyen C; Hendra H; Vogel M; Hoffmann C; Knechten H; Brockmeyer NH; Bogner JR; Rockstroh J; Esser S; Jaeger H; Harrer T; Mauss S; van Lunzen J; Skoetz N; Jetter A; Groneuer C; Fätkenheuer G; Khoo SH; Egan D; Back DJ; Owen A;
    J Antimicrob Chemother; 2008 Apr; 61(4):914-8. PubMed ID: 18281305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.
    Haas DW; Gebretsadik T; Mayo G; Menon UN; Acosta EP; Shintani A; Floyd M; Stein CM; Wilkinson GR
    J Infect Dis; 2009 Mar; 199(6):872-80. PubMed ID: 19239339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?
    Micheli JE; Chinn LW; Shugarts SB; Patel A; Martin JN; Bangsberg DR; Kroetz DL
    Pharmacogenet Genomics; 2013 Nov; 23(11):591-6. PubMed ID: 23982262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection.
    Langaee T; Al-Shaer MH; Gong Y; Lima E; Antwi S; Enimil A; Dompreh A; Yang H; Alghamdi WA; Wiesner L; Peloquin CA; Kwara A
    Infect Genet Evol; 2021 Aug; 92():104856. PubMed ID: 33839311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.
    Chantarangsu S; Cressey TR; Mahasirimongkol S; Capparelli E; Tawon Y; Ngo-Giang-Huong N; Jourdain G; Lallemant M; Chantratita W
    J Antimicrob Chemother; 2009 Dec; 64(6):1265-73. PubMed ID: 19812066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon.
    Paganotti GM; Russo G; Sobze MS; Mayaka GB; Muthoga CW; Tawe L; Martinelli A; Romano R; Vullo V
    Infect Genet Evol; 2015 Oct; 35():122-6. PubMed ID: 26247717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.
    Schipani A; Wyen C; Mahungu T; Hendra H; Egan D; Siccardi M; Davies G; Khoo S; Fätkenheuer G; Youle M; Rockstroh J; Brockmeyer NH; Johnson MA; Owen A; Back DJ;
    J Antimicrob Chemother; 2011 Jun; 66(6):1332-9. PubMed ID: 21441248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
    Swart M; Skelton M; Ren Y; Smith P; Takuva S; Dandara C
    Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
    Saitoh A; Sarles E; Capparelli E; Aweeka F; Kovacs A; Burchett SK; Wiznia A; Nachman S; Fenton T; Spector SA
    AIDS; 2007 Oct; 21(16):2191-9. PubMed ID: 18090046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.
    Vardhanabhuti S; Acosta EP; Ribaudo HJ; Severe P; Lalloo U; Kumarasamy N; Taulo F; Kabanda J; Oneko O; Ive P; Sambarey P; Chan ES; Hitti J; Hong F; McMahon D; Haas DW;
    J Infect Dis; 2013 Aug; 208(4):662-71. PubMed ID: 23687222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.
    Rotger M; Colombo S; Furrer H; Bleiber G; Buclin T; Lee BL; Keiser O; Biollaz J; Décosterd L; Telenti A;
    Pharmacogenet Genomics; 2005 Jan; 15(1):1-5. PubMed ID: 15864119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.
    Mhandire D; Lacerda M; Castel S; Mhandire K; Zhou D; Swart M; Shamu T; Smith P; Musingwini T; Wiesner L; Stray-Pedersen B; Dandara C
    OMICS; 2015 Sep; 19(9):553-62. PubMed ID: 26348712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
    Reay R; Dandara C; Viljoen M; Rheeders M
    OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
    Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
    Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosage optimization of treatments using population pharmacokinetic modeling and simulation.
    Guidi M; Arab-Alameddine M; Rotger M; Aouri M; Telenti A; Decosterd LA; Buclin T; Csajka C;
    Chimia (Aarau); 2012; 66(5):291-5. PubMed ID: 22867538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.